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cdc28Cyclin-dependent kinase 2 (cdk2) is a central regulator of the mammalian cell cycle. Here we describe the
properties of a mutant form of cdk2 identiﬁed during large-scale sequencing of protein kinases from
cancerous tissue. The mutation substituted a leucine for a proline in the PSTAIRE helix, the central motif in
the interaction of the cdk with its regulatory cyclin subunit. We demonstrate that whilst the mutant cdk2 is
considerably impaired in stable cyclin association, it is still able to generate an active kinase that can
functionally complement defective cdks in vivo. Molecular dynamic simulations and biophysical
measurements indicate that the observed biochemical properties likely stem from increased ﬂexibility
within the cyclin-binding helix.ces, Imperial College, South
302.
 license.© 2010 Elsevier B.V. Open access under CC BY license.1. Introduction
The central regulators of mammalian cell proliferation are the
cyclin-dependent kinases (cdks) that phosphorylate key substrates in
a sequential manner to facilitate orderly progression through the cell
cycle [1,2]. Commitment to division is determined in the G1 phase of
the cell cycle, a timewhen the predominantly active cdks are cdk2 and
cdk4 [2]. These cdks are activated sequentially in part through
interaction with their regulatory subunits, the D-type cyclins binding
to cdk4 early in G1 phase, with E-type cyclins associating with cdk2 in
mid-G1, and with A-type cyclins combining with cdk2 in S phase [2].
Genetic studies have largely validated this view although they have
also uncovered considerable functional redundancy amongst the cdks
[1].
Association of cyclins with their cognate cdk subunit typically
involves interaction over a large surface area that is centred on the so-
called PSTAIRE helix of the cdk [3,4], this being equivalent to the C
helix in protein kinase A [5]. In associating with cdk2, E-type cyclins
cause an essential rearrangement of the PSTAIRE helix to a
conformation favouring the full activation of the cdk (the so-called
‘helix in’ arrangement) [6]. Together with the phosphorylation of akey threonine in the activation segment (also known as the T loop)
adjacent to the catalytic site, the PSTAIRE helix rearrangements upon
cyclin binding lead to the realignment of essential ATP binding
residues into an active conformation.
Because of their central regulatory role in proliferative control,
cdks (along with other signal transducing protein kinases) have
become the focus of much interest in the study of diseases affecting
proliferation, such as cancer. In order to gain insight into mutations
that may affect kinase function, large-scale sequencing projects have
been directed at identifying abnormalities in the fraction of the
genome encoding the protein kinases in cancerous tissue [7]. Such
studies have the power to uncover many mutations in focussed
screens of interesting candidate genes although they do not in
themselves address the functional consequences of detected muta-
tions. Here we describe the characterisation of the properties of one
missense mutation in cdk2 detected by the Cancer Genome Project
that alters the proline of the PSTAIRE helix to a leucine in a
glioblastoma cell line.
2. Materials and methods
2.1. Antibodies
The following antibodies were used: cyclin E1 (HE12), p21 (C-19),
p27 (C-19) and cdk2 (sc-163) from Santa Cruz and anti-Flag (M2)
859E.S. Child et al. / Biochimica et Biophysica Acta 1803 (2010) 858–864antibody from Sigma. Anti-cyclin A2 (E65.1) was from Cancer
Research UK. HRP-conjugated secondary antibodies (mouse, rabbit
and goat) were from Jackson ImmunoResearch.
2.2. Plasmids and viruses
The P45Lmutant cdk2was generated by site-directedmutagenesis
and, after sequence veriﬁcation, subcloned into pBlueBacHis A
(Invitrogen). This was transfected into Sf9 cells with linearised viral
DNA (BaculoGold, BD Biosciences) and recombinant virus ampliﬁed to
generate high titre baculovirus stock. The P45L mutant cdk2 was also
cloned into pcDNA3 for mammalian expression. In addition, the P45L
mutant cdk2 was cloned into the yeast two-hybrid vector pGBDU-C1
[8]. Control constructs/viruses were created with wild type cdk2.
Other recombinant baculoviruses encoding full-length cyclins E1 and
A2 have been described [9]. Coding sequences for p21 and p27 were
cloned into pRSET and expressed in bacteria. Proteinswere puriﬁed by
metal immunoafﬁnity puriﬁcation following treatment of sonicated
lysates at 65 °C for 10 min and removal of the precipitated material.
2.3. Cell culture
Sf9 cells were grown in Graces insect media (PAA) supplemented
with 10% foetal bovine serum (PAA) and maintained at 27 °C. The Sf9
cells were infectedwith baculoviruses directing the expression of wild
type or P45L mutant cdk2, cyclin A2, cyclin E1 and/or wild type virus
at multiplicities of infection greater than 10:1. U2OS cells were grown
in DMEM supplementedwith 10% foetal bovine serum in a humidiﬁed
atmosphere containing 10% carbon dioxide in air at 37 °C. The cells
were transfected with pcDNA3-cdk2 and cdk2 P45L by calcium
phosphate precipitation [9]. The transfected cells were washed 24 h
later and after a further 24 h the cells were harvested.
2.4. Yeast methods
Saccharomyces cerevisiae strain Y246a (MATa cdc28-4 trp1 ura3-52
tyr1; a gift from John Difﬂey) was transformed with plasmids using
lithium acetate. Transformants were plated on selective media and
incubated at permissive (30 °C) or restrictive (35 °C) temperatures for
three days.
2.5. Kinase assays
Sf9 cells infected with the appropriate recombinant baculoviruses
were lysed 72 h post infection by hypotonic lysis using kinase buffer
(25 mM Hepes pH7.9/5 mM MgCl/0.1% 2-mercaptoethanol/0.1 mM
EDTA) for 10 min on ice. Cell debris was removed by centrifugation.
The cell lysate was used in kinase assays as described below. In
immunoprecipitation kinase assays, immunoprecipitations were
performed at 4 °C for 2 h using protein A-Sepharose beads, cdk2
antibody (0.4μg) in PBS/0.1% Tween 20. The beads were washed three
times in PBS/0.1% Tween 20, followed by two further washes in kinase
buffer. Kinase assays were performed in kinase buffer containing 0.5–
1 μg Histone H1 or GST-pRb, 100 μM ATP and 2.5 μCi [γ32P]-ATP and
incubated for 30 min at 30 °C. Reactions were terminated by the
addition of an equal volume of 2× SDS-PAGE loading buffer and
resolved by SDS-PAGE and then subject to autoradiography.
2.6. Immunoprecipitations
Cells were washed in PBS and then lysed in 0.1% Tween 20/
150 mM NaCl/1 mM DTT/50 mM Tris–HCl pH8.0/1 mM EDTA/
2.5 mM EGTA/50 mM NaF at 4 °C by passing the lysate ﬁve times
through a 21 gauge needle. Debris was removed by centrifugation.
Lysates were then immunoprecipitated as described above. The
precipitates were washed three times in lysis buffer, resuspended in2× SDS-PAGE loading buffer and immunoblotted with detection via
chemiluminescence visualised on Fuji Image Reader LAS-3000.
2.7. Circular dichroism
A Chirascan spectropolarimeter (Applied Photphysics) was used to
measure the CD spectra and temperature-dependent protein unfold-
ing proﬁles [10]. A 0.1 cm path length was used with a protein
concentration of 0.1 mg/ml in buffer containing 10 mM Tris–HCl pH
8.0/150 mM NaCl/10% glycerol/1 mM DTT. Tm was determined at
230 nm with temperature range from 20 to 80 °C (recorded every
0.5 °C).
2.8. Thermal shift assays
Sypro Orange™ (Invitrogen) was added to a solution of cdk2 (5–
10 μg) in 20 or 40 mM Tris–HCl pH8.0/150 mM NaCl/1 mM DTT/5%
glycerol (total volume 95 μl) in a 96-well plate. The samples were
heated from 20 to 90 °C at intervals of 0.5 °C, each held for 10 s on an
IQ5 Real-Time PCR Detection System (BioRad). The ﬂuorescence
intensity was measured at excitation/emission wavelengths of 485/
530 nm and the Tm was calculated as the temperature of maximum
inﬂection of the melting curve.
2.9. Computational methods
Molecular dynamics simulationswere carried out using the program
PMEMD (from AMBER 9.0 package) [11] with the parm99 and ff03 force
ﬁelds [12,13]. The ff03 force ﬁeld is the most recent version of AMBER
force ﬁeldwith revised ψ/φ torsion parameters and recalculated atomic
partial charges from theelectrostatic potential in the continuum(εr=4)
produced by the B3LYP/cc-pVTZ method. The parm99 force ﬁeld does
not accurately represent glycine behavior and that is prone to other
inaccuracies including over-stabilisation ofα-helical peptide conforma-
tions andover-estimationofβ-bendpropensity. Nonetheless, both force
ﬁelds are believed to perform well on compact and folded protein
structures. The cdk2 starting structure (PDB code: 2CLX, resolution 1.8 Å
with the ligand removed from the active site [14]) and the starting
structure for pT160-cdk2/ATP complexedwith Cyclin E was taken from
PDB (PDB code: 1W98, resolution 2.15 Å [6], where ATP and Mg2+ was
added from 1JST structure [15]). The applied MD simulation protocol,
whichhas been repeatedly successfully used to study cdk2 systems [16–
19], was as follows. First, the protonation states of all histidines were
checked using WHATIF [20] to create an optimal H-bond network. All
hydrogens were added using the Xleap program from the AMBER 9.0
package. The structures were neutralized by adding 4 Cl− counter ions
to the monomeric cdk2 systems and 7 Cl− counter ions to the systems
complexed with cyclin E. Each system was solvated in a rectangular
water box with a layer of water molecules 9 Å thick. The energy of each
system was then minimized as follows prior to the main molecular
dynamics simulation run. The protein was frozen and the solvent
molecules and counterions were allowed to move during a 1000 step
minimization and a 10 ps long molecular dynamics run under NpT
conditions. The side chains were then relaxed using several sequential
minimizations with the force constants applied to the backbone atoms
being decreased in each run. Following this relaxation, the system
was 20 ps heated from 10 to 50 K, then 70 ps from 50 to 298.16 K and
the thermalization was ended by 10 ps warming at 298.15 K. The
production phases were run for 10 ns for all systems. Free cdk2 system
studied comprised∼35000 atoms and cdk2-cyclin E systems comprised
∼70000 atoms. The simulation period was chosen as a compromise
between the quality of conformation space sampling and the calculation
length. Time integration steps of 2 fs were used, together with particle-
mesh Ewald (PME) methods for electrostatic interactions. All simula-
tionswere rununderperiodic boundary conditions in theNpTensemble
at 298.16 K and at a constant pressure of 1 atm. The SHAKE algorithm
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hydrogen atoms. Non-bonding interactions were subject to a 9.0 cut-
off. Coordinates were stored every 2 ps. All analyses of the MD
simulations were carried out using the PTRAJ modules of AMBER 9.0.
3. Results
During large-scale sequencing to identify mutations in protein
kinases in human cancer cells and primary tissue, we identiﬁed a
heterozygous missense mutation in the cdk2 gene in a short-term
culture of a glioblastoma (data not shown). The mutation was in the
cdk2 kinase at position 45, altering the conserved proline of the
cyclin-binding PSTAIREmotif to a leucine (P45L, hereafter). This motif
is characteristic of many cdks and is central to the binding of the
activating cyclin subunit to the kinase [4]. Inspection of the crystal
structures of cdk2/cyclin E1 [6] revealed that the proline side chain
was oriented away from the cyclin subunit (not shown)making direct
side chain effects on cyclin binding unlikely. However, given the
importance of this region in regulating cdk activity, the presence of
this mutation in a cancer cell line, the constraints imposed by proline
in terms of peptide backbone angles and the non-conservative nature
of the substitution involved, we undertook to characterise the
properties of this P45L cdk2 to determine if they could be contributory
to deregulated cell cycle control.
Initially, we constructed a recombinant baculovirus directing
expression of the mutant form of cdk2. This virus produced somewhat
lower levels of recombinant protein than the wild type cdk2-encodingFig. 1. P45L cdk2 is functional as a protein kinase. A Sf9 cells were co-infected with recombin
with non-recombinant baculovirus. Cell lysates were immunoblotted as indicated. B Sf9 c
assayed for kinase activity against both GST-Rb and Histone H1 using [γ-32P]ATP followed
concentrations of p27 puriﬁed from recombinant bacteria for 10 min at room temperature
0 denotes assays performed in the absence of p27. Assays were performed in triplicate and
deviation with activities normalised to the uninhibited control. E S. cerevisiae with a tempe
type or P45L cdk2 or the parental vector and tested for their ability to proliferate at 30 °C avirus and the protein displayed a slightly enhanced mobility on SDS-
PAGE (Fig. 1A) perhaps indicative of differences in retained secondary
structure during electrophoresis. Co-infection of Sf9 cells with either
recombinant baculovirus directing expression of wild type or P45L
cdk2 and either an A- or E-type cyclin was performed and the kinase
activity of the cell lysates assessed. Fig. 1B demonstrates that both
forms of cdk2 generated kinase activity towards both Histone H1 and
the Retinoblastoma protein, Rb. Themutant enzyme produced slightly
less kinase activity than the wild type but this parallelled its reduced
expression. The activities of both wild type and P45L cdk2 in complex
with cyclin E1 (or cyclin A2) were equally sensitive to the cdk
inhibitors p21 and p27 when titrated into the in vitro assays (Fig. 1C
and D and Fig. S1).
To further demonstrate the functionality of the P45L mutant cdk2,
we expressed it in S. cerevisiae containing a temperature sensitive
allele of cdc28 and tested for complementation at the restrictive
temperature. As shown in Fig. 1E, P45L cdk2 enabled proliferation at
the non-permissive temperature although proliferation was generally
less robust than that of yeast expressing wild type cdk2 in agreement
with previous observations [21]. Taken together, these experiments
demonstrate that the P45L mutation in cdk2 is seemingly well
tolerated and the kinase produced had gross properties that were
similar to its wild type counterpart being functional both in vitro and
in vivo.
Whilst the data suggested that the P45L cdk2 was functional, this
mutant version of the enzyme appeared somewhat less efﬁcient that
the wild type equivalent in terms of expression in Sf9 cells, kinaseant baculoviruses encoding wild type cdk2 or P45L cdk2 plus cyclin E1 or were infected
ells were infected with the indicated recombinant baculoviruses, lysed after 72 h and
by autoradiography. C and D Lysates as described in A were incubated with increasing
and then incubated for 30 min at 30 °C in the presence of Histone H1 and [γ-32P]ATP.
quantiﬁed by Phosphorimage analysis. The bar chart shows the means and standard
rature sensitive allele of cdc28 were transformed with plasmids expressing either wild
nd the restrictive 35 °C. Two individual transformants are shown for each plasmid.
Fig. 2. P45L cdk2 fails to stably associate with cyclins. A and B Sf9 cells were infected with the indicated recombinant baculoviruses, lysed after 72 h and immunoprecipitated
through cdk2. Total cell lysates and immunoprecipitates were immunoblotted as indicated (A) or immunoprecipitates were used in kinase assays with Histone H1 as substrate (B).
C and D U2OS cells were transfected with Flag-tagged wild type or P45L cdk2 and cell lysates were harvested and immunoprecipitations were performed through the Flag tag
of the cdk2. Total lysates (Total) and immunoprecipitates (IP) were immunoblotted for the Flag epitope and total cdk2 showing exogenous (white circle) and endogenous
(black circle) expression and cyclin E. Kinase assays against GST-Rb were also performed (D, lower panel).
Fig. 3. P45L cdk2 is more stable than its wild type counterpart. A CD spectra of cdk2
(blue) and P45L cdk2 (red) at 20 °C from 200 to 260 nm. The yellow line delineates the
buffer control. B Denaturation curves for cdk2 (blue) and P45L cdk2 (red) at 230 nm
from 20 to 80 °C. For all CD data, representative plots are shown from three
independent repeats.
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understand these observations further, we investigated the interac-
tion of cyclins with this mutant cdk. Initially we used the baculovirus
system to generate cell lysates expressing both cdk2 (wild type or
P45L mutant) and cyclin E1. Lysates were immunoprecipitated
through cdk2 and immunoblotted for the associated cyclin. As
shown in Fig. 2A, cyclin E1 was readily detected in association with
wild type cdk2 but only present at very low levels in the P45L cdk2
immunoprecipitates despite being present in the initial lysate at levels
similar to the wild type protein. Further, immunoprecipitation kinase
assays also demonstrated a lack of activity associated with the mutant
kinase (Fig. 2B) when compared to its wild type counterpart.
To validate this data, we performed similar experiments in human
cells. U2OS cells were transfected with plasmids directing expression
of Flag-tagged cdk2 (wild type or P45L mutant) and immunopreci-
pitated through the epitope tag. Immunoblotting the precipitates
again demonstrated that the P45L mutant cdk2 failed to stably
associate with cyclin E whereas this cyclin was readily detectable in
the precipitates with the wild type cdk2 construct (Fig. 2C). Similar
results were obtained when the immunoprecipitation was performed
through either cyclin E1 or A2 (Fig. S2). This difference was also
observed in immunoprecipitation kinase assays (Fig. 2D).
This biochemical evidence suggested that the P45L cdk2 was
impaired in stable interaction with the cyclin subunit. We hypothe-
sized that the mutation of the proline in the PSTAIRE helix may
increase the ﬂexibility in that region of the protein allowing the cdk to
sample a greater ensemble of structures not all of which were
permissive for cyclin binding. We reasoned that such an effect may be
observed in a change in the thermal stability of cdk2. To test this idea
we isolated poly(His)-tagged cdk2 (wild type and P45L mutant) from
recombinant bacteria and performed circular dichroism (CD) and
thermal denaturation assays. CD revealed wild type and P45L cdk2
proteins had very similar spectra indicating no gross differences in
protein secondary structure (Fig. 3A). We next assessed cdk2 thermalstability by CD at 230 nm between 20 °C and 80 °C. From three
separate determinations, wild type cdk2 melted at a lower temper-
ature than the P45L mutant cdk2 (Tm 53.7 °C vs 58.1 °C, mean of two
Table 1














Wild type cdk2 parm99 10 1.9±0.1 14.4 17.4
ff03 30 1.7±0.1 14.3 16.7
P45L-cdk2 parm99 30 1.9±0.1 16.4 30.1
ff03 30 1.7±0.1 23.7 33.3
pT160-cdk2/ATP/
cyclin E1
parm99 10 3.7±0.2 6.1 11.9
ff03 30 3.2±0.2 4.2 6.2
pT160-P45L-cdk2/
ATP/cyclin E1
parm99 10 1.8±0.2 6.8 5.1
ff03 30 3.2±0.1 6.0 5.5
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second thermal stability test, this time with a ﬂuorescence-based
assay using the environmentally sensitive dye, Sypro Orange. Again,
themutant protein was signiﬁcantly more thermostable than the wild
type (Tm 51.15±0.13 °C vs 52.03±0.35 °C, mean±SD, P=0.0151 by
t test; Fig. S3).
To further elucidate the role of the P45L mutation on cdk2 and
cdk2/cyclin E complex structure and dynamics, we performed
molecular dynamics (MD) simulations of the following systems (see
Table 1 for overview): monomeric wild type or P45L mutant cdk2 and
both kinases (the threonine 160 phosphorylated form) in complex
with cyclin E1 (and ATP). The convergence and the stability of the MD
trajectories were documented by time evolution of root-mean-square
deviation (RMSD) of heavy atoms from the X-ray structures (Fig. S4).
The RMSD of all systems become balanced after ∼3 ns then systems
reached their equilibrated states and remained ﬂuctuating around theFig. 4.Molecular dynamics simulations of cdk2 variants. Images showing the average structu
acid 45 of the cdk2 is indicated by arrows in each panel, with the proline coloured yellow a
C parm99 and D ff03 depict cyclin E1/cdk2 complexes.average values (Table 1). These RMSDs show that MD simulations
were convergent and ready for further structural analyses.
The typical bilobal kinase fold is retained in all structures (Fig. 4).
The largest differences between wild type cdk2 and P45L cdk2
occurred in the PSTAIRE helix, which contacts the regulatory cyclins
and β3-PSTAIRE helix connecting loop. (A number of exposed loops
also showed substantial structural deviations but given the inherent
ﬂexibility of such regions [18] we did not consider them further.)
Residue P45 at the N-terminus of PSTAIRE helix in wild type cdk2 is
partially exposed to the solvent. In the crystal structure of the cdk2/
cyclin E1, the PSTAIRE helix contacts cyclin E1 and adopts its rotated
inner conformation, which allows hydrogen bond between E51 from
PSTAIRE and K31 and thus the P45 residue is rotated into the cdk2
protein too. The mutant structures of monomeric cdk2 differed in
both PSTAIRE helix position and β3-PSTAIRE loop conformation from
wild type structures (Fig. 5). The PSTAIRE helix of the mutant
structures is rotated from its native position by 16 degrees (Fig. 5).
While β3-PSTAIRE loop conformations of the wild type align well, the
loop conformations of the P45L mutant differed from the wild type
signiﬁcantly, one being localized below and one above the confor-
mation of the wild type loop, indicating greater ﬂexibility of this
region in agreement with analysis of temperature B-factors.
Temperature B-factors (Bf) provide information about thermal
ﬂuctuations of amino acids. The Bf values were calculated from the last
1 ns of the MD simulations (Fig. S5). In all cases, Bf values of the
PSTAIRE helix (residues 45–59) were higher for P45Lmutants than for
the wild types in agreement with the increased ﬂexibility of the P45L
cdk2 in this region. The Bf values of both wild type cdk2/cyclin E1 and
P45L cdk2/cyclin E1 systems were similar to one another differing in
ﬂexibility within the activation segment (parm99 simulation, maxi-
mum at residue 156) of cdk2 (Table 1). More variation was observedres over the last 1 ns of simulations with proteins coloured according to the key. Amino
nd the leucine green. A parm99 and B ff03 depict monomeric wild type and P45L cdk2.
Fig. 5. Structural differences predicted between wild type and P45L cdk2. Superposition
of monomeric cdk2 structures averaged over the last ns of MD simulations, cdk2
(parm99) in dark blue, cdk2 (ff03) in light blue, P45L cdk2 (parm99) in dark green and
P45L cdk2 (ff03) light green. The yellow arrow indicates the β3-PSTAIRE loop and an
angle between the axes of PSTAIRE and LSTAIRE helices (red lines) is 16°.
Fig. 6. CIP/KIP inhibitors can stabilise the P45L cdk/cyclin E1 complex. Sf9 cells were
co-infected with recombinant baculovirus encoding cyclin E1, wild type cdk2 or P45L
cdk2 in the absence and presence of p21-encoding virus. Cell lysates were
immunoprecipitated through cdk2 and immunoprecipitations were immunoblotted
as indicated.
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residues 252–256 which are oriented toward the activation segment
of cdk2 and residues 339–347, a solvent exposed ﬂexible loop lying
adjacent to residues 252–256 (Fig. S5). The Bf of P45 and L45 does not
substantially differ in cyclin-bound cdk2 with both being lower than
Bfs of the respective residues of monomeric cdk2.
The rotated position of PSTAIRE helix and increased ﬂexibility
around the PSTAIRE helix in P45L cdk2 suggested by the MD
simulations could provide an explanation for the reduced binding of
this cdk with cyclins observed biochemically. The cdk inhibitors p21
and p27 have been shown to help in the assembly and stabilisation of
D-type cyclin/cdk complexes [22,23]. Given the lack of stable
interaction between the P45L cdk2 and cyclins, we asked if p21
could stabilise this cdk/cyclin interaction. Again, Sf9 cells were
infected with baculovirus directing expression of cdk2 (wild type or
mutant) and cyclin E1 in the absence or presence of p21-encoding
virus. Cells were lysed and immunoprecipitated through the cdk and
immunoblotted for the cyclin and p21. Fig. 6 clearly demonstrates that
p21 was able to substantially stabilise the mutant cdk/cyclin
interaction. Similar results were obtained with cyclin A2 (not shown).
4. Discussion
Activating mutations in protein kinases are increasingly recog-
nised as driver mutations in various forms of cancer [7]. We have
analysed the P45L mutation in the cell cycle regulator cdk2 found
through targeted genomic sequencing of a glioblastoma and affecting
the PSTAIRE cyclin-binding helix characteristic of cdks. The mutation
does not appear to cause gross alterations to the cdk2 structure as
indicated by the retention of biological activity and the similarity of
the wild type and mutant CD spectra. Our analysis reveals interesting
features of cdk2 biochemistry but does not suggest that this mutation
is likely to be causal for cancer.
The interaction of cyclins and cdks relies upon a large interface
(3252 Å2 for cyclin E1/cdk2 [6]) centred on the PSTAIRE helix of the
cdk subunit. In the crystal structure of cyclin E1/cdk2 [6] and cyclin
A2/cdk2 [4,15], the PSTAIRE helix lies almost parallel to the α5 helix
of the cyclin and this cyclin helix is also adjacent to the loopconnecting β3 and the PSTAIRE helix. These closely aligned regions
make numerous hydrophobic interactions and hydrogen bonds in the
cyclin E1/cdk2 and cyclin A2/cdk2 crystal structures [4,6]. The major
difference observed biochemically between the wild type and P45L
cdk2 proteins was the reduced ability of the mutant to maintain
association with its cognate cyclin over prolonged periods. MD
simulations indicate that the P45L mutation leads to a greater degree
of ﬂexibility in the β3-PSTAIRE helix loop as well as a displacement of
the PSTAIRE helix in themonomeric kinase subunit and these analyses
provide a potential explanation for the reduced stable association of
this mutant kinase with its regulatory cyclin subunits observed
experimentally.
Despite the lack of stable cyclin binding, P45L cdk2 displayed
enzymatic activity very similar to the wild type kinase when assayed
in lysates of recombinant baculovirus-infected Sf9 cells (the P45L
mutant cdk2 retained ∼62% of the activity of wild type cdk2 in an Sf9
cell lysate although this activity is almost entirely lost during
immunoprecipitation). One explanation for this observation could
be a weaker, transient association between cyclin and cdk favoured in
lysates over-expressing cyclins and cdks allowing occasional activa-
tion. Alternatively, it may be possible that the kinase assay conditions
(high levels of ATP, protein substrate and kinase components) may
stabilise the active cyclin/cdk complex permitting substrate phos-
phorylation whereas the immunoprecipitation assay conditions (no
added ATP, dilute components) are not favourable for complex
stability. The in vivo rescue of yeast expressing a temperature
sensitive variant of CDC28 also provides compelling evidence that
P45L cdk2 is functional in a cellular setting, delivering sufﬁcient
catalytic activity to allow cell cycle progression.
The ability of the cdk inhibitor p21 to facilitate stable complex
assembly between the P45L cdk2 and a cyclin is reminiscent of the
dual role of p21 in the activation of D-type cyclin/cdks [22,23].
However, to our knowledge, there are no reports of cdk2 kinase
activity being sustained in the face of cdk inhibitor binding binding
making this is an unlikely mechanism to account for the kinase
activity we observed in cell lysates or the rescue of proliferation in the
cdc28ts yeast. However, it is possible that other cellular chaperones
account for the assembly activity required for these events; it is
known, for example, that D-type cyclin/cdk complexes have assembly
factors other than p21 and p27 [24,25] and such mechanisms may
864 E.S. Child et al. / Biochimica et Biophysica Acta 1803 (2010) 858–864account for P45L cdk2/cyclin complexation, with chaperones perhaps
facilitating short-term interactions that are not maintained during the
extended periods of immunoprecipitation experiments.
Isolation of the P45Lmutant of cdk2 from a glioblastoma raised the
possibility that the mutation could be a contributory factor to the
aetiology of the disease. Our ﬁndings on the properties of the protein
suggest that this is most likely not to be the case. Although the
mutation produces a kinase that is functional in vitro and in vivo, the
enzyme is impaired in its ability to form a stable association with its
activating cyclin subunits. Thus, this mutation alone is unlikely to be a
driver of oncogenesis, although in the context of the genomic
instability associated with cancer, it is possible that other genetic
alterations may inﬂuence its function.
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